INMB实时信号 | 通过Getagraph.com最大化利润

购买 107739 min ago

@ $14.06

发出时间: 15 Feb 2024 @ 04:50

回报率: -15.93%

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:23):

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease...

Stats
今日成交量	105 511
平均成交量	102 404
市值	221.03M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-0.540 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.08
ATR14	$0.0490 (0.41%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Moss David J	Buy	18 028	Common Stock
2024-04-19	Moss David J	Buy	18 028	Common Stock Warrants (right to buy)
2024-04-19	Tesi Raymond Joseph	Buy	18 028	Common Stock
2024-04-19	Tesi Raymond Joseph	Buy	18 028	Common Stock Warrants (right to buy)
2024-04-19	Lowdell Mark William	Buy	14 423	Common Stock

INSIDER POWER
97.72
Last 100 transactions
Buy: 3 367 309 \| Sell: 701 956

音量相关性

長: 0.19 (neutral)

短: 0.42 (neutral)

Signal:(64.277) Neutral

INmune Bio Inc 相关性

10 最正相关
ECPG	0.878
FIVN	0.859
TREE	0.855
IPDN	0.844
PIRS	0.843
CWBR	0.833
LCFY	0.83
STX	0.828
NXST	0.828
PALT	0.826

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

INmune Bio Inc 相关性 - 货币/商品

-0.23
( neutral )

-0.24
( neutral )

0.00
( neutral )

0.28
( neutral )

0.39
( neutral )

0.44
( neutral )

INmune Bio Inc 财务报表

Annual	2023
营收:	$155 000
毛利润:	$155 000 (100.00 %)
EPS:	$-1.670

FY	2023
营收:	$155 000
毛利润:	$155 000 (100.00 %)
EPS:	$-1.670

FY	2022
营收:	$374 000
毛利润:	$374 000 (100.00 %)
EPS:	$-1.600

FY	2021
营收:	$-181 000
毛利润:	$0.00 (0.00 %)
EPS:	$-1.751

Financial Reports:

No articles found.

INmune Bio Inc

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

实时更新： INmune Bio Inc [INMB]

Upcoming Earnings Alert